Cancer Tech Accelerator · Phase 2

Commercialisation modules for CTA 5.0 finalists

A structured diagnostic programme for deep-tech, oncology and life science founders — translating scientific mechanism into defensible commercial value.

What the diagnostic returns

GTM archetype

Mapped to peer benchmarks

Readiness score

0–100 commercial index

Execution gap

Founder bandwidth vs. Phase 2

Method

Strategy is 10%.Execution is 90%.

Every module ends with a quantified gap and the next commercial move.